Podcasts about treatment options

Think beyond the esophagus. Up to 75% of eosinophilic esophagitis (EoE) patients have ENT-relevant atopic disease that is often best managed with a multidisciplinary approach. Get caught up on best practices in EoE diagnosis and treatment with this episode of the BackTable ENT Podcast, featuring dual board-certified gastroenterologist and allergist-immunologist Dr. John Leung and host Dr. Basil Kahwash. --- SYNPOSIS The discussion covers the definition, symptoms, and diagnosis of EoE, highlighting the role of food and environmental allergies. Dr. Leung and Dr. Kahwash cover diagnostic techniques like endoscopy and emerging non-invasive methods, as well as various treatment options including dietary modifications, pharmacology, and biologics. The doctors also emphasize the importance of multidisciplinary collaboration between gastroenterologists, allergists, and otolaryngologists to provide optimal care for patients with EoE. --- TIMESTAMPS 00:00 - Introduction 03:13 - Understanding Eosinophilic Esophagitis (EoE)05:45 - EoE Symptoms and Diagnosis08:41 - Role of ENT in EoE Diagnosis11:32 - Diagnostic Criteria for EoE16:34 - Treatment Options for EoE20:55 - Role of Allergists and Environmental Allergies23:24 - Pharmacological Management of EoE29:38 - Complications and Risks of EoE36:21 - Follow-Up Endoscopies and Surveillance40:34 - Future Directions in EoE Management45:21 - Conclusion and Final Thoughts --- RESOURCES Dr. John Leunghttps://www.bostonspecialists.org/dr-leung-full-profile

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Dr. Jim Dunlap discusses one of the honorable mention articles of 2024, titled “Early Surgery Versus Exercise Therapy and Patient Education for Traumatic and Nontraumatic Meniscal Tears in Young Adults—An Exploratory Analysis From the DREAM Trial,” which was originally published in the Journal of Orthopaedic & Sports Physical Therapy in April 2024. Dr. Jeremy Schroeder serves as the series host. Dr. Dunlap is a member of the Top Articles Subcommittee, and this episode is part of an ongoing mini journal club series highlighting each of the Top Articles in Sports Medicine from 2024, as selected for the 2025 AMSSM Annual Meeting. Early Surgery Versus Exercise Therapy and Patient Education for Traumatic and Nontraumatic Meniscal Tears in Young Adults—An Exploratory Analysis From the DREAM Trial: https://www.jospt.org/doi/full/10.2519/jospt.2024.12245

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn't an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Topics include the prioritization of treatment versus tissue acquisition, the nuances of bronchoscopic versus percutaneous biopsies, and the latest advancements in robotic and cryo-biopsy techniques. The experts also share their approaches to managing pneumothorax, the value of multidisciplinary collaboration, and case studies that highlight personalized patient care. Listeners gain valuable insights into the evolving landscape of thoracic oncology procedures and the importance of patient-centered decision-making. --- TIMESTAMPS 00:00 - Introduction04:12 - Cryobiopy vs. Non-Cryobiopsy08:43 - Biopsy and Ablation: Strategies and Considerations15:31 - Post-Therapy Imaging and Follow-Up25:18 - Treatment Options and Patient Decisions27:08 - Evaluating Ablation Techniques28:59 - Managing Lung Cancer Recurrence39:41 - Case Study: Young Male with Ground Glass Nodule43:15 - Concluding Thoughts

Send us a textA lot of parents have difficulty to understand that just because they have Myopia, that doesn't mean their children will. However it's proven that genetics is one factor, and there are some significant others like amount of time spent near and far from a screen, education levels etc. I've had 15 years in my practice talking with parents about the importance of their children having regular eye exams and making them aware of the technological advances in this field. On today's episode of The Myopia Podcast, I will share with you some treatment options for Myopia and how you can present them to parents effectively. 

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University. Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists. Episode Highlights: • Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab • Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer • Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers • Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies • TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management • Expert consensus on infusion reaction management for novel biologics • The importance of managing baseline symptoms in patients with dysphagia and nausea This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Peripheral Neuropathy: Causes, Symptoms, And New Treatment Options When nerves lose the energy they need to function, it leads to numbness, pain, and loss of mobility for millions of Americans. New research is uncovering how risk factors like obesity, high blood pressure, and food insecurity disproportionately affect certain communities. As scientists work to refine treatments and explore promising therapies that include GLP-1 medications, early detection, dietary changes, and improved access to healthcare remain critical to stopping the progression of this condition. How Improving Healthcare For People With Disabilities Helps Everyone Special Olympics is working to close major gaps in healthcare for people with intellectual and developmental disabilities. A new global report reveals widespread problems – from poor provider training to communication barriers – that prevent individuals with IDD from receiving informed, respectful, and effective care. The organization hopes to create a more inclusive system by improving physician training and empowering people with IDD to participate in their own health decisions. Medical Notes: We're Overusing Salt, How Feeding Birds Improves Our Quality Of Life, And Protecting Kids From HIV How can we save babies born with HIV? We're overusing salt – and not just in our pasta. Technology is only as good as it's creator. Is it time to invest in a bird feeder? Learn more about your ad choices. Visit megaphone.fm/adchoices

Faith and mental health collide as we unpack religious psychosis - from recognizing hallucinations and delusions with spiritual themes to understanding genetic and cultural causes. Discover how treatment combines therapy, medication, and support to help individuals reclaim reality without abandoning their spirituality. Visit https://amfmtreatment.com/blog/understanding-religious-psychosis-symptoms-causes-treatment/ A Mission for Michael (AMFM) City: San Juan Capistrano Address: 30310 Rancho Viejo Rd. Website: https://amfmtreatment.com/

When nerves lose the energy they need to function, it leads to numbness, pain, and loss of mobility for millions of Americans. New research is uncovering how risk factors like obesity, high blood pressure, and food insecurity disproportionately affect certain communities. As scientists work to refine treatments and explore promising therapies that include GLP-1 medications, early detection, dietary changes, and improved access to healthcare remain critical to stopping the progression of this condition. Learn more about your ad choices. Visit megaphone.fm/adchoices

Schizophrenia is a mental disorder characterised by impairments in the way reality is perceived with associated changes in behaviour. We cover the symptoms of Schizophrenia (with delusion types), including the DSM-5 criteria for diagnosis, as well as Schizophrenia treatment. PDFs available here: https://rhesusmedicine.com/pages/psychiatryConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Schizophrenia?0:28 Schizophrenia Symptoms - Positive Symptoms2:28 Schizophrenia Symptoms - Negative Symptoms2:58 Schizophrenia Symptoms - Cognitive Symptoms 3:49 Schizophrenia Diagnosis / Diagnostic DSM 5 Criteria 5:08 Schizophrenia Causes / Pathophysiology 5:53 Schizophrenia Risk Factors & Epidemiology 7:00 Schizophrenia Treatment LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesNational Institute of Mental Health (NIMH), 2025. Schizophrenia. [online] Available at: https://www.nimh.nih.gov/health/topics/schizophrenia.World Health Organization (WHO), 2025. Schizophrenia. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.National Alliance on Mental Illness (NAMI), 2025. Schizophrenia. [online] Available at: https://nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizophrenia.Wikipedia, 2025. Schizophrenia. [online] Available at: https://en.wikipedia.org/wiki/Schizophrenia.Medscape, 2025. Schizophrenia: Symptoms, Causes & Treatment Options. [online] Available at: https://emedicine.medscape.com/article/288259-overview.Symptom Media, 2025. Schizophrenia Delusions: Definition, Types, and Treatments. [online] Available at: https://symptommedia.com/delusions-associated-with-schizophrenia-ce-course-preview/.Psycom, 2025. Schizophrenia: Symptoms, Causes, Diagnosis, Treatment. [online] Available at: https://www.psycom.net/schizophrenia.StatPearls, 2025. Schizophrenia. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK539864/.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

Story PreviewExperience the often-misunderstood journey through perimenopause and menopause. Dr. Ladan Hariri describes the confusing hormonal shifts, emotional challenges, and physical changes women navigate, offering insights into treatment and lifestyle adjustments.Chapter Summary:00:00 Understanding Menopause and Perimenopause04:28 Impact of Symptoms and Cultural Differences08:59 Hot Flashes, Sleep, and Relationship Challenges14:35 Brain Remodeling and Health Risks20:00 Embracing the Journey of Womanhood23:16 Treatment Options and Emerging Therapies28:30 Diet, Environment, and Hormone Disruptors32:20 Ancient Wisdom and Future AdvocacyFeatured Quotes:“Menopause is the official time when your period hangs up its hat, officially retires.” — Dr. Hariri“If menopause is your final destination, perimenopause is the really, really, really unpredictable road trip to get there.” — Dr. Hariri“Women actually require 10 hours of uninterrupted sleep, compared to our male counterparts who do just fine with 7 to 8 hours.” — Dr. HaririBehind the Story:The episode explores the complex realities of perimenopause and menopause, highlighting that perimenopause can start much earlier than commonly believed, impacting women from their early 40s. Dr. Hariri discusses cultural differences in managing these life stages and the broader societal factors, such as diet and environmental hormone disruptors, that contribute to early onset. The conversation also touches on the importance of prioritizing sleep and recognizing heart disease symptoms, which often present differently in women.

Send me a question or story!Solar dermatitis (actinic keratosis) is skin damage from prolonged UV exposure, affecting both dogs and cats, particularly those with light-colored or thin coats. So, pets that have white fur and live in high UV exposure areas (like the southern US) are predisposed. Symptoms include redness, scaling, hair loss, and thickened, crusty skin. Commonly affected areas include the nose, ears, abdomen, and inner thighs. This condition can lead to more severe issues, including pre-cancerous lesions and aggressive skin cancer like squamous cell carcinoma. We will discuss ways to identify this disease and treatment options such as CO2 laser ablation, etc.00:00 – Intro04:06 – Nasal Solar Dermatitis06:32 – Classic Canine Solar Dermatitis08:15 – Treatment Options for Solar Dermatitis16:52 – Outro

PPPD (AKA: persistent postural perceptual dizziness) is a chronic form of dizziness which is very manageable. But everyone wants to know “is there a cure for PPPD?”  To get to that answer, we've got to go all the way back to the beginning to uncover why PPPD is happening in the first place. Because PPPD is always caused by another underlying diagnosis. It's both under and overly diagnosed—and this episode is built to be a resource for you. So you can finally feel empowered to understand what's going on and what to do about it next. In this episode, we'll dig into: What persistent postural perceptual dizziness (PPPD) is What symptoms are mistakenly associated with PPPD What generally makes PPPD better or worse Places and events that are more challenging with PPPD What usually triggers PPPD How PPPD is diagnosed Personality types that are more likely to have PPPD Why dizziness and anxiety are so closely linked If there is a cure for PPPD What the Wheel of Management is The best treatment options for PPPD You do not need to be dizzy everyday for the rest of your life. PPPD is treatable, but you need a treatment plan that works for you.  A great place to start is VGF! Support, education, and community—all of that plus more resources than you can imagine are waiting for you in Vestibular Group Fit. If you're in the holiday challenge and listening today, please send me a DM for extra credit. Links: Neurahealth (virtual neurology, use code VERTIGODOCTOR15 for 15% off) Vestibular Group Fit (code GROUNDED at checkout!) Join Vestibular Virtual Summit Waitlist Related Episodes: Episode 5: Can We Break The Dizzy Anxious Dizzy Cycle? with Dr. Emily Kostelnik, PhD⁠ Episode 40: ⁠The Importance of Hope and Mindset for Vestibular Migraine with Dr. Emily Kostelnik, PhD⁠ More Links/Resources: ⁠The 4 Steps to Managing Vestibular Migraine ⁠The PPPD Management Masterclass⁠ ⁠What your Partner Should Know About Living with Dizziness⁠ ⁠The FREE Mini VGFit Workout⁠ ⁠The FREE POTS - safe Workouts⁠ ⁠Vestibular Group Fit (code GROUNDED at checkout for 15% off your first subscription cycle!) ⁠ Connect with Dr. Madison: ⁠@⁠⁠TheVertigoDoctor ⁠ ⁠@TheOakMethod⁠ ⁠@VestibularGroupFit⁠ Connect with Dr. Jenna @dizzy.rehab.therapist  Work with Dr. Madison 1:1, Vestibular Rehabilitation Therapy Vestibular Group Fit Small Group Coaching (offered throughout the year, sign up for our email list to learn when!) Why The Oak Method? Learn about it here! Love what you heard? Reviews really help us out! Please consider leaving one for us.  This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— Can PPPD be cured, what is PPPD, what is pppd disease, pppd symptoms, persistent postural perceptual dizziness treatment, chronic dizziness, diagnostic criteria, vertigo, vestibular disorder, vestibular migraine, BPPV, anxiety disorder, low tox lifestyle, mindset shift, autonomic dysregulation, PPPD management, nervous system regulation

In this episode of The Performance Medicine Show, Dr. Rogers answers YOUR health and wellness questions! What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine⁠⁠⁠⁠⁠

Dr. Faisal Khan talks about how treatment of Asthma and COPD has evolved and new options to help patients with ongoing management of their condition.

If you've ever been told your FSH is too high or that you're not a good candidate for IVF, today's episode will help you understand what that number actually means and the many ways you can still support your fertility. When most people hear "high FSH," they immediately think poor ovarian reserve or low egg count. That's not the full story. In this episode, we look at what high FSH signals, how to interpret it alongside other markers, and what both conventional and functional fertility options can help you move forward with clarity. You'll learn: • What high FSH actually measures and why context matters when paired with AMH, estradiol, and AFC • How inflammation, stress, thyroid imbalance, sleep, and environmental toxins influence FSH • Conventional treatment options such as mini IVF, natural cycle IVF, Letrozole, and individualized stimulation protocols • How functional fertility improves the internal environment so your ovaries respond better to any treatment • The key labs, nutrients, and lifestyle factors that support egg quality and hormone communication in high FSH cases This episode is especially for you if: • You've been told you have high FSH or diminished ovarian reserve and worry the window is closing • You've had canceled IVF cycles or poor responses and want to understand what else you can do • You want to see how a functional fertility approach can support egg quality so your next steps feel strategic and not desperate Sarah Clark is the founder of Fab Fertile Inc. and the host of Get Pregnant Naturally. Her team specializes in functional approaches for low AMH, high FSH, diminished ovarian reserve, premature ovarian insufficiency, recurrent miscarriage and helping couples prepare their bodies for pregnancy success naturally or with IVF. Next Steps in Your Fertility Journey Subscribe to Get Pregnant Naturally for evidence-based guidance on functional fertility, and share this episode with anyone on their fertility journey. Not sure where to start? Download our most popular guide:  Ultimate Guide to Getting Pregnant This Year If You Have Low AMH/High FSH it breaks everything down step by step to help you understand your options and take action For personalized support to improve pregnancy success, book a call here. --- TIMESTAMPS 00:00 – What High FSH Really Means for Fertility What FSH actually measures, why it does not reflect egg quality, and why high FSH is often misunderstood in conventional fertility care. 01:00 – The Emotional Impact of High FSH and Canceled IVF Cycles Understanding why high FSH triggers fear, how it influences IVF decisions, and how a functional lens shifts your strategy. 02:00 – Real Case Story: FSH in the 60s Reduced to 7 A Fab Fertile client lowered FSH dramatically after three failed IVFs and conceived with her own eggs after being told donor eggs were the only option. 03:00 – Drivers of High FSH: Inflammation, Stress, Thyroid, Sleep, and Toxins FSH as feedback, not failure. Exploring how inflammation, poor sleep, blood sugar imbalance, thyroid dysfunction, and environmental toxins impact ovarian response. 04:00 – Conventional Treatment Options for High FSH Mini IVF, natural-cycle IVF, Letrozole, Clomid, individualized protocols, medication dosing considerations, and how clinics determine next steps. 05:00 – Why Medication Alone Isn't Enough: The Functional Fertility Lens How functional testing identifies hidden blocks like gut infections, food sensitivities, chronic inflammation, nutrient deficiencies, and nervous system dysregulation. 06:00 – Hidden Stressors That Disrupt Egg Quality and Hormone Signaling Parasites, H. pylori, bacterial overgrowths, mold exposure, toxin load, fragrances, plastics, and irregular cortisol patterns that impact egg development. 09:00 – Key Fertility Labs for High FSH Optimal vs normal ranges for thyroid markers, vitamin D, ferritin, fasting insulin, A1C, homocysteine, and how methylation affects hormone detox and ovarian health. 12:00 – Functional Testing That Personalizes Your Fertility Plan GI-MAP, food sensitivity testing, DUTCH hormone mapping, genetic testing (MTHFR, COMT, GST), and vaginal microbiome tests for implantation and inflammation insights. 18:00 – When to Pause IVF and Re-Evaluate Your Strategy Why repeating protocols isn't effective when the internal environment isn't optimized. When a 3–6 month reset can improve ovarian response and IVF success. 19:00 – Final Takeaway: High FSH as a Message, Not a Verdict High FSH is information, not a dead end. How combining functional optimization with conventional care improves egg quality, hormone signaling, and overall fertility outcomes. RESOURCES

Vision loss is never a purely clinical journey. As Dr. Jennifer Lyerly shares at the start of this Defocus Media episode, geographic atrophy affects patients emotionally, socially, and psychologically. Optometrists, therefore, play a central role in offering meaningful support throughout the entire geographic atrophy experience—especially as new treatment options, including Izervay, enter the landscape.

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios. --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The doctors share treatment strategies, staging processes, and post-therapy patient management techniques. They address recurrent disease, approaches to different stages of cancer, the role of biomarkers in determining treatment paths, and considerations for both high-risk and intermediate-risk patients. Additionally, the episode touches on new treatments, clinical trials, and patient quality of life post-treatment. --- TIMESTAMPS 00:00 - Introduction02:08 - Case Study: Initial Patient Assessment04:59 - Surgical Considerations and Techniques10:22 - Managing Bladder Cancer Recurrence11:15 - Treatment Options and Clinical Trials15:12 - Advanced Treatment Strategies28:14 - Closing Remarks and Credits --- RESOURCES VISTA Trial https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non BRIDGE Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/ CORE-008 Trialhttps://www.sciencedirect.com/science/article/abs/pii/S1078143924010147 GAIN Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10176900/

In this episode of the MamasteFit YouTube channel, certified nurse midwife Roxanne discusses iron deficiency anemia in pregnancy. She explains the importance of hemoglobin and iron in red blood cells, symptoms of anemia, and the necessity of increased iron due to the doubling of blood volume during pregnancy. Roxanne outlines how iron deficiency anemia is screened through blood tests and indicates hemoglobin and ferritin levels. She discusses potential treatments including dietary changes, iron supplements, and more severe interventions like iron or blood transfusions. Roxanne also shares her personal experience with iron deficiency anemia and offers insights on managing the condition. She emphasizes the importance of detecting and treating iron deficiency anemia to prevent potential complications like postpartum hemorrhage and preterm birth. Check out MamasteFit's online courses and fitness programs for additional support.00:00 Introduction to Iron Deficiency Anemia in Pregnancy00:37 Understanding Anemia and Its Impact01:32 Iron's Role in Pregnancy02:21 Preventing and Screening for Anemia04:52 Symptoms and Diagnosis of Iron Deficiency Anemia06:19 Treatment Options for Iron Deficiency Anemia07:02 Personal Experience and Recommendations09:28 Conclusion and Additional Resources————

In this engaging conversation, Dr. Angela Petersen discusses her journey from traditional nursing to regenerative medicine, emphasizing the importance of hormone optimization and the challenges posed by the current healthcare system.    Dr. Angela details her transition from traditional nursing to regenerative medicine due to her deep passion for helping people reclaim their health.   She critiques the influence of pharmaceutical advertising and the misconceptions surrounding health and healthcare treatments. Dr Angela and Nick also discuss the challenges of the healthcare system in the United States and how it prioritizes pharmaceutical profits over patient wellness.   They also explore the details of how the U.S. healthcare system often treats symptoms rather than addressing root causes, and the heavy influence of pharmaceutical advertising on public perception of health and wellness.   The discussion also touches on the role of influencers in health, the significance of nutrition, and how the political landscape misleads people about health and wellness products.   Getting back to the basics, Dr. Angela shares her expertise on key fundamentals in our health, such as the importance of nitric oxide for circulation, sodium for hydration and cellular function, and how processed foods and seed oils contribute to chronic health issues.   She also shares best practices and treatments for hormone regulation, optimal cellular function, and the significance of receiving personalized care from your physicians.    Dr. Angela introduces her book, 'The Wellness Glitch,' which aims to address the systemic issues in healthcare and promote better health practices. Chapters   00:00 Introduction to Dr. Angela Peterson 02:46 The Evolution of Healthcare and Longevity 05:42 Challenges in Traditional Medicine 08:39 The Influence of Pharmaceutical Advertising 11:51 The Impact of SSRIs and Mental Health 14:43 The Role of Influencers in Health and Wellness 17:51 Understanding Erectile Dysfunction and Treatment Options 26:06 The Importance of Nitric Oxide 28:55 Cellular Activity and Peptides 30:23 The Role of Sodium in Health 33:18 Debunking Dietary Myths 38:08 The Politics of Food and Health 46:43 Vaccines and Public Health Concerns 52:55 The Complexity of COVID Vaccination 57:45 Fear and Compliance During the Pandemic 01:01:43 Exploring Health Glitches and Societal Issues 01:07:38 Angela's Book: The Wellness Glitch 01:15:52 Authenticity and Personal Experiences Find Angela Peterson here: Instagram: https://www.instagram.com/amplified_total_wellness/ | https://www.instagram.com/amplified1209/  Website: www.ampdhealth.net  The Wellness Glitch Book: https://tinyurl.com/ycy3stz9    Find Nick Thompson here: Instagram: https://www.instagram.com/nthompson513  | https://www.instagram.com/the_ucan_foundation      YouTube: https://www.youtube.com/@EyesWideOpenContent     LinkedIn: https://www.linkedin.com/in/nickthompson13/       UCAN Foundation: https://theucanfoundation.org    Website: https://www.engagewithnick.com/     

In this episode of The Pediatric Pharmacist Review, we explore the phenomenon of seasonal affective disorder (SAD) and its relevance to children, adolescents, and families. Our guest, Tim Horton, is a seasoned psychiatric nurse‑practitioner (APRN, CNP) and founder of PeopleFirst Clinic in Woodbury, Minnesota, where he specializes in holistic, medication‑management and therapy‑integrated care for youth and adults. With his unique background in pediatric mental health, patient‑centered approaches, and collaborative provider work, Tim brings deep insight into how biological and environmental factors converge in seasonal depression—and what practical actions caregivers and clinicians can take to mitigate its impact. Key Discussion Points: Biological & Environmental Contributors: We unpack how changes in daylight exposure, circadian rhythm shifts, neurotransmitter variations (serotonin, melatonin), and geographic/seasonal factors contribute to SAD in children and teens. Lifestyle & Environmental Interventions: Tim and I discuss actionable strategies such as structured light‑exposure (dawn simulators, 10,000 lux boxes), daily outdoor activity, consistent sleep schedules, and nutritional supports (timing of meals, nutrient‑dense foods, healthy fats) to reduce symptom severity. Treatment Options & Efficacy: We review standard of care for SAD—starting with behavioral and lifestyle measures, then progressing to light therapy and pharmacologic treatment (SSRIs, SNRIs, augmentation) when needed, including considerations unique to pediatric populations. Vitamin D and Seasonal Depression: We examine the evidence linking vitamin D deficiency with increased SAD risk, discuss screening thresholds in younger patients, supplementation strategies, and how this fits into a broader preventive mindset. Preventive Measures Ahead of Winter: Tim outlines a pre‑winter readiness plan—adjusting indoor lighting, optimizing outdoor daylight exposure, establishing routine exercise, reinforcing healthy diet patterns, and monitoring early warning signs for a proactive response. Misconceptions and Under‑Recognition: We address common myths—such as SAD only occurring in extreme northern latitudes, or that “it's just the blues” and will self‑resolve—highlighting how under‑recognition in pediatric settings can delay helpful intervention. Resources & Links: Tim Horton LinkedIn: https://www.linkedin.com/in/tim-horton-248858359/ PeopleFirst Clinic: https://www.peoplefirstmn.com/

You don't have to suffer through the leaks or the frequent, inconvenient trips to use the restroom. Dr. Annaceci Peacher discusses what causes these incontinence issues and outlines treatment options offered at Tidelands Health that can help bring permanent relief and restore your quality of life.  Learn more about Dr. Peacher

Send Us A Question!In this episode, we're tackling one of the most common—and complex—cardiac conditions seen in feline practice with the one and only Dr. Heather Davis: hypertrophic cardiomyopathy (HCM). From recognizing early indicators to understanding the latest treatment advances, this conversation is designed to help veterinary professionals stay sharp on current HCM management.Episodes release bi-weekly on Thursdays at 9am EST and are available on all podcast platforms including a video version on YouTube!Have a question or inquiry for the podcast? Email questionswithcrocker@gmail.com, text us from the link above, or message on social media platforms.00:00 Intro03:00 Effects of HCM in Cats06:14 Prevalence of HCM in Specific Breeds07:29 Screening Options for HCM13:25 Age Prevalence for HCM Detection15:21 GP Brief Echo Tips19:00 Treatment Options for HCM21:15 What Is Felycin-CA1?24:35 Things To Look Out For With Felycin-CA126:08 How Effective Is Felycin-CA127:55 Availability and Pricing of Felycin-CA130:29 How To Administer the Tablet32:40 Other Common Questions36:45 Outro

Septal Perforations Symptoms, Causes, and Fixes with Dr. Samir Undavia If you've been told you have a "hole in your nose," you're likely dealing with a septal perforation. In this episode of We Nose Noses, Dr. Samir Undavia walks through what that means, who to see first, the most common causes (from prior nasal surgery to medication technique and trauma), how ENTs pinpoint the reason, and the realistic treatments, from saline care and ointments to septal buttons and surgical repair. Clear, step-by-step guidance to help you breathe easier and decide next steps from the experts at NJENT. What you'll learn: What a septal perforation is and the key symptoms How ENTs figure out the cause and what tests they use Treatment options at a glance: care, buttons, surgery Think you have a septal perforation? Schedule a consult with NJ ENT & Facial Plastic Surgery to get your perforation characterized, identify the cause, and review the best treatment for your symptoms and goals.  https://njent.com/help-theres-a-hole-in-my-nose-causes-and-treatment-options/  

Girlfriend, maybe you've been struggling with disordered eating for decades and you don't want to put your life on hold to go into a full-blown treatment facility. Maybe you have kids at home, aging parents to care for, or a career you can't walk away from. Or maybe you don't even know what options are available, so you just stay stuck thinking you'll manage it all by yourself. Girl, you weren't meant to do this alone. In this episode, host Lindsey Nichol breaks down the 6 different levels of eating disorder treatment and care - from outpatient support to acute medical stabilization - so you can understand what's available and what might be best for YOUR unique situation and life circumstances. Lindsey shares her own treatment journey through IOP and day treatment, and why finding the right level of care that fits your life is so important. Whether you're a busy mom, working woman, caregiver, or someone who simply can't leave home for residential treatment, this episode will help you understand all your options - including recovery coaching as a personalized support option. You deserve a life free from the chains of disordered eating. And it starts with knowing what treatment options are out there. In This Episode, You'll Learn: The 6 Levels of Eating Disorder Treatment: Level 1: Outpatient Care What it is: Weekly sessions with a care team while living at home Who it's for: Those deemed medically stable who need ongoing support What's included: Dietitian, therapist, medical doctor, support groups Best for: Maintaining school, work, family life while getting treatment Level 2: Intensive Outpatient Program (IOP) What it is: Multiple sessions per week in specialized settings Where it happens: Treatment centers or hospitals What's included: Group therapy, individual therapy, structured programming Lindsey's experience: This is where she spent the majority of her recovery Level 3: Partial Hospitalization Program (PHP) / Day Treatment What it is: 5-6 days per week, 6-8 hours per day Structure: More intensive than outpatient, includes meals and therapies What happens: You return home in the evenings Lindsey's experience: Combined with IOP while in school - included therapies and support groups Level 4: Residential Treatment What it is: 24-hour care and supervision (inpatient experience) Who it's for: Those medically stable but requiring intensive support Where it happens: Medical hospitals, centers, or homelike facilities Structure: Full-time structured environment with comprehensive care Level 5: Inpatient Hospitalization What it is: Most appropriate for high-intensity medical/psychiatric needs Structure: 24-hour medical psychiatric facility Who it's for: Those not responding to other treatments, experiencing self-harm, severe depression, or needing intensive medical oversight Level 6: Acute Medical Stabilization What it is: The highest level of critical care for eating disorders Who it's for: Those medically unstable due to severity or medical complications Primary focus: Physical stabilization before moving to other treatment levels Plus: Recovery Coaching as a Treatment Option What it is: One-on-one virtual support for guided accountability and actionable recovery steps Who it's for: Those who can't or won't go into residential but need support How it works: Weekly sessions focused on action, not diagnosis Can be layered: Works alongside therapy, dietitian, and medical care Key Takeaways: ✨ Treatment is personalized - what works for someone else may not work for you, and that's okay ✨ You don't have to choose residential - there are multiple levels of care that allow you to stay home ✨ Recovery is NOT black and white - you can get support at various levels based on your life circumstances ✨ You weren't meant to do this alone - even if you can't go to residential, you need SOME level of support ✨ Everyone's recovery is their own - your journey is unique and valid regardless of which level of care you choose ✨ Recovery coaching is a valid option - especially when layered with other care team members ✨ You owe you, sister - putting yourself first isn't selfish, it's necessary ✨ More options exist now - compared to years ago, there are so many more treatment options available Powerful Quotes from This Episode: "You deserve a life that's free from the chains of disordered eating" "Maybe you don't even know what options are available for you, so you just stay here thinking you're gonna manage it all by yourself" "Everyone's recovery is your recovery. Your journey is your journey" "What's best for you might not be best for me. What worked for me might not work for someone else" "You weren't meant to do life alone. You definitely weren't meant to do the hard things alone" "You owe you, sister" "It's not black and white. There's so many other options" "What matters is that you're standing up for you" "You are worth it. You deserve it" "Everyone else in your life is gonna benefit when you can start putting you first" Important Information About Each Treatment Level: When to Consider Outpatient: You're medically stable You can maintain work/school/family responsibilities You need ongoing support and accountability You're in maintenance or relapse prevention phase When to Consider IOP: You need more structure than weekly appointments You can still live at home You benefit from group support You need multiple therapy modalities When to Consider PHP/Day Treatment: You need daily structure but can return home at night You require meal support You need more intensive care than IOP You're transitioning from residential or preventing residential When to Consider Residential: You need 24-hour support but are medically stable Your home environment isn't supportive of recovery You need complete immersion in treatment Outpatient options haven't been effective When to Consider Inpatient: You're experiencing severe symptoms There's self-harm or suicidal ideation You need medical and psychiatric oversight You require the highest level of structure When to Consider Recovery Coaching: You can't or won't do residential treatment You have kids, aging parents, or career obligations You want actionable support, not diagnosis You're looking for relapse prevention You want to layer support with existing care team What Makes Recovery Coaching Different: Not therapy: Coaches don't diagnose or address trauma - they focus on forward action Accountability structure: Weekly sessions keep you committed to your recovery goals Actionable support: Focused on practical steps like facing fear foods, getting off the scale, eating out with family Virtual and flexible: Fits into busy lives with kids, work, caregiving responsibilities Layered care: Works alongside dietitians, therapists, and medical professionals Relapse prevention: Helps maintain recovery after intensive treatment Questions to Ask When Choosing Treatment: What level of medical stability am I at currently? What are my life circumstances? (Kids, work, caregiving, school) Can I leave home for treatment, or do I need to stay local? What treatment options are available in my area? What does my insurance cover? Do I need 24-hour support or can I manage with weekly sessions? Am I willing to commit to doing the work required at each level? What has or hasn't worked for me in the past? Do I have a support system at home? What does my healthcare team recommend? Action Steps After This Episode: Assess where you are: Are you medically stable? What symptoms are you experiencing? Talk to a healthcare professional: Schedule appointments with your doctor to discuss which level of care is appropriate Research local options: Google treatment centers, IOP programs, PHP programs in your area Consider online options: Virtual recovery coaching, online support groups, telehealth therapy Build your care team: Even if you can't do residential, assemble support (dietitian, therapist, coach, doctor) Stop doing this alone: Commit to getting SOME level of support starting today Reach out: If recovery coaching interests you, visit lindseynickel.com to learn more Who This Episode Is For: This episode is essential listening if you: Don't know what eating disorder treatment options exist Think residential is your only option (and you can't do it) Have been doing this alone and need to know what help is available Are a busy mom, working woman, or caregiver who can't leave home Have been in treatment before and need to know what's next Are researching options for a loved one struggling with disordered eating Want to understand the difference between IOP, PHP, and residential Need permission to choose the treatment level that fits YOUR life Are looking for alternatives to inpatient treatment Want to layer recovery coaching with your existing care team Resources Mentioned: National Alliance for Eating Disorders: Information on treatment levels and resources National Eating Disorders Association (NEDA): Comprehensive treatment information and support Recovery Coaching with Lindsey: One-on-one virtual support, weekly sessions, actionable recovery tools Her Best Self Facebook Community: Support group for women in recovery Important Reminder: Lindsey is NOT a medical professional. The information in this episode is based on her personal experience and education but should not replace consultation with a licensed healthcare professional. Always speak with your doctor, therapist, or treatment team to determine which level of care is most appropriate for your specific situation. Connect with Lindsey Website: www.herbestself.co  Private Facebook Community: Her Best Self Society www.herbestselfsociety.com  Client Applications: HBS Co. Recovery Coaching - Client Application - Google Forms About the Host Lindsey Nichol is a former competitive figure skater turned God-led entrepreneur, boy mom, and digital CEO. She understands how core beliefs formed in childhood can create and maintain eating disorder patterns, and she's passionate about helping women identify and transform these beliefs to find lasting freedom. If this episode helped you identify the core beliefs feeding your eating disorder, please share it with someone who needs to hear this message. Your support helps more women break the chains of limiting beliefs. *While I am a certified health coach, anorexia survivor & eating disorder recovery coach, I do not intend the use of this message to serve as medical advice. Please refer to the disclaimer here in the show & be sure to contact a licensed clinical provider if you are struggling with an eating disorder.

Today's episode is one I've really been looking forward to because we're diving into something that's transforming the way we think about mental health treatment: low-dose ketamine therapy. My guest, Dr. Sharon Niv, is the co-founder of Joyous, a public benefit company helping make this kind of care more accessible and affordable than ever before. Sharon brings a fascinating background in cognitive psychology, meditation, and technology, and she's helping bridge the gap between neuroscience and therapy in a way that's incredibly gentle, safe, and empowering for both clients and clinicians. We'll talk about what makes psycholytic, or low-dose, ketamine different from traditional psychedelic experiences, how it can enhance the therapeutic process, and how you, as a therapist, can get trained to integrate it into your own work. This is one of those conversations that opens your mind to what's possible in therapy, so let's jump in. Resources Mentioned In This Episode Use the promo code "GORDON" to get 2 months of Therapy Notes free Consulting with Gordon The PsychCraft Network Profit First for Therapists Workbook Meet Sharon Niv, Ph.D. Dr. Sharon Niv is a cognitive psychologist and co-founder of Joyous Team, a Public Benefit Corporation dedicated to making evidence-based mental health treatments accessible and affordable. Her work bridges the worlds of neuroscience, technology, and therapy with a focus on how scalable, data-driven approaches can enhance emotional well-being. Dr. Niv earned her Ph.D. in Brain and Cognitive Science from the University of Southern California, where she conducted research on EEG biomarkers, neurofeedback, and the neural underpinnings of mood and behavior. She also holds a B.A. in Molecular and Cellular Biology from UC Berkeley and an M.A. in Clinical and Cognitive Psychology from USC. Before founding Joyous, Sharon worked on developing virtual-reality interventions for chronic pain and neurofeedback programs designed to help people improve emotional regulation and resilience. A long-time meditation practitioner, she combines scientific rigor with a deep understanding of mindfulness and experiential learning. Through Joyous, Sharon and her team are pioneering low-dose (psycholytic) ketamine therapy, creating safer, more sustainable pathways for individuals and therapists to experience healing and insight. Her mission is to empower both clinicians and clients with practical tools that promote neuroplasticity, compassion, and mental clarity. The Power of Therapy + Joyous Joyous Substack LinkedIn

This week, Aebhric talks with Jason Jarvis, a former Special Forces medic and current PhD candidate, and discusses Chagas disease, a tropical disease transmitted by the kissing bug. He explains the life cycle of the bug, the transmission of the disease, its clinical presentation, and the challenges in diagnosis and treatment. The conversation emphasises the importance of awareness and preventive measures, especially as Chagas disease is spreading to new regions, including parts of the United States. The discussion concludes with key take-home messages for healthcare providers and the need for ongoing education in tropical medicine.TakeawaysChagas disease is transmitted by the kissing bug, primarily in Central and South America.The life cycle of the kissing bug involves several stages, including the transmission of the parasite through its faeces.Clinical diagnosis is essential, especially in endemic areas where the disease is prevalent.The acute phase of Chagas disease is easier to treat than the chronic phase, which can lead to severe complications.Preventive measures include avoiding exposure to kissing bugs and ensuring blood products are screened for the disease.Chagas disease can also be transmitted through blood transfusions and organ transplants.Healthcare providers should be aware of the symptoms and risk factors associated with Chagas disease.The disease is now spreading to parts of the continental US, raising public health concerns.Ongoing education and awareness of tropical diseases are crucial for healthcare providers.The conversation highlights the importance of understanding the global health implications of diseases like Chagas. Chapters00:00 Introduction to Chagas Disease and Its Relevance02:36 Life Cycle of the Kissing Bug and Transmission of Chagas Disease04:58 Understanding the Pathophysiology of Chagas Disease07:31 Clinical Presentation and Diagnosis of Chagas Disease10:18 Chronic Phase and Long-term Effects of Chagas Disease12:41 Treatment Options and Challenges in Managing Chagas Disease14:51 Preventive Measures and Risk Factors for Chagas Disease17:39 Chagas Disease in the Context of Global Health19:42 Take-Home Messages for Healthcare Providers22:20 Future Considerations and Closing Thoughts

Interview with Jorge Romero, MD

As Parkinson's symptoms change over the years, different treatments may be needed to best manage symptoms and side effects. Since last fall, the U.S. Food and Drug Administration has approved five new options for people living with the disease, including two continuous, under-the-skin infusion pumps. Tune into audio from this Third Thursday's Webinar to hear our panel of experts discuss these options and other strategies to treat progressing Parkinson's disease.Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmi.Mentioned in this episode:The Foundation's landmark research study is exploring the connection between sense of smell and brain disease. People with and without Parkinson's can help by taking a free scratch-and-sniff test. Get yours at mysmelltest.org/request.

Not all pain is visible and not all solutions are obvious, especially in chronic pelvic pain. In this episode of BackTable OBGYN, host Dr. Mark Hoffman welcomes Dr. Aakriti Carrubba, an expert in minimally invasive gynecological surgery and pelvic pain from the Mayo Clinic, to talk through the evaluation and treatment of chronic pelvic pain.---SYNPOSISDr. Carrubba shares her journey from Kentucky to Florida, detailing her extensive training and interest in managing pelvic pain. The discussion covers the evaluation of pelvic pain, the significance of a thorough patient history and systematic pelvic exams, and the role of interdisciplinary approaches, including physical therapy and pain management. Dr. Carrubba emphasizes the importance of addressing central sensitization and chronic pain syndromes, explaining that not all pain can be attributed solely to structural abnormalities. The episode also touches on the integration of advanced AI tools in medical practice to enhance patient documentation and overall care.---TIMESTAMPS00:00 - Introduction01:09 - Dr. Carrubba's Background and Journey03:54 - Fellowship Experience and Pelvic Pain Focus06:44 - Approach to Chronic Pelvic Pain14:04 - Detailed Pelvic Pain Exam Techniques17:14 - Trigger Point Injections and Their Role21:33 - Challenges in Pain Management and Education26:34 - Role of Central Sensitization in Chronic Pelvic Pain29:35 - Approach to Central Sensitization and Screening33:13 - Approaches to Excision Surgery36:04 - Post-Surgery Management and Hormonal Suppression38:19 - Teaching and Training in Pelvic Pain Management41:35 - Pain Rehabilitation Clinic for Central Sensitization44:59 - Teaching Pelvic Pain Anatomy to Trainees48:24 - Advancements in AI for Medical Documentation52:26 - Reflections on Pelvic Pain Training and Education56:00 - Final Thoughts

More than half of U.S. adults experience dry eye symptoms, but only a small fraction have received a formal diagnosis or treatment Common symptoms include burning, stinging, gritty sensations, blurred vision, and eye fatigue, often worse at night or with prolonged screen use Environmental and lifestyle factors — including digital device use, indoor HVAC, contact lenses, and certain medications — are major drivers of dry eye disease Remedies range from simple lifestyle changes and home routines (blink breaks, warm compresses, humidifiers) to over-the-counter drops, prescription medications, and device therapies Ignoring persistent symptoms increases the risk of corneal damage, chronic inflammation, and permanent vision changes, making professional evaluation necessary

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:Brief overview of BTC and GEAApproved HER2-directed therapies for BTC and GEA and their mechanisms of actionEfficacy and toxicities of the approved agents and optimal management strategiesKey ongoing trials of HER2-directed therapies in BTC and GEAChallenges faced by healthcare professionals in the management of patients with BTC and/or GEA PresentersAmit Mahipal, MD, MPHDirector, Gastrointestinal Medical Oncology ProgramRuth and Donald Goodman Endowed Chair in GI OncologyProfessor of Medicine, Senior Attending PhysicianUniversity Hospitals Siedman Cancer CenterCase Comprehensive Cancer CenterCase Western Reserve UniversityCleveland, OhioShubham Pant, MDProfessorDepartment of Gastrointestinal (GI) Medical OncologyDepartment of Investigational Cancer TherapeuticsDirector of Clinical ResearchAssociate Director for Early Phase Drug DevelopmentSheikh Ahmed Bin Zayed Al Nahyan CenterMD Anderson Cancer CenterHouston, TexasLink to full program:https://bit.ly/3KL2ank Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsWhat happens when the “healthy one” gets cancer? Samantha Harris shares the diagnosis that changed everything.In this deeply moving episode of Hol+, Dr. Taz MD sits down with Emmy-nominated TV host, author, and breast cancer survivor Samantha Harris to unpack her harrowing and empowering health journey—from being blindsided by a breast cancer diagnosis at 40, to navigating a recurrence a decade later, despite living what she thought was the healthiest lifestyle.Best known as the radiant host of Dancing with the Stars and Entertainment Tonight, Samantha takes us behind the scenes of her transformation from fitness icon to fierce advocate, author, and functional health warrior. She opens up about her fight to be taken seriously by doctors, why mammograms failed to detect her cancer, and the powerful philosophy she developed in the aftermath: “10% Toxic.”This conversation is packed with raw honesty, actionable insights, and the kind of wisdom that only comes from walking through fire—twice.Samantha opens up about:How a “normal” mammogram nearly cost her everythingThe misdiagnosis that delayed her treatment for monthsHer decision to skip chemo and radiation—and why she still doesn't regret itThe power of intuition in healing and early detectionHow to build your “doctor squad” and advocate for yourselfHer 10% toxic philosophy to reduce overwhelm and reclaim wellnessHow she now supports women around the world through her book, podcast, and retreatsWhether you've faced cancer, know someone who has, or simply want to prevent disease in a world full of overwhelm, this episode offers real talk, real tools, and real hope.Connect further to hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.About Samantha HarrisA 4-time Emmy Award nominee, she's best known for lighting up our screens for 8 unforgettable seasons as the host of Dancing with the Stars—and she also won the Emmy for her years on Entertainment Tonight! She's the only host to have ever anchored every major national entertainment news program from Access Hollywood and EXTRA to E! News and more.But behind the bright lights, life took an unexpected turn. At just 40 years old, this devoted wife and mom of two young daughters faced a shocking breast cancer diagnosis. A decade later, at 50, she was blindsided yet again by a recurrence. But Samantha Harris didn't just survive—she redefined what it means to thrive. She turned her journey into a mission—becoming a Certified Health Coach, and the bestselling author and dynamic host of the top-rated podcast, Your Healthiest Healthy. You've seen her as a trusted health expert on Good Morning America, FOX & Friends, The Doctors, HLN's Morning Express, and more—sharing practical, life-changing wellness strategies. As a National Ambassador for the world's largest breast cancer foundation, Susan G. Komen, she's on a mission to uplift, empower, and equip others to take control of their health like never before—one manageable step at a time.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Samantha Harris​https://samantha-harris.com/https://www.instagram.com/samanthaharristv/Host & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+Chapters00:00 Introduction02:43 Samantha's Health Journey Begins05:28 Navigating the Medical System07:21 Making Treatment Decisions15:38 Treatment Options and Outcomes31:32 Recovery and Genetic Testing32:54 The Journalist's Deep Dive into Breast Cancer34:15 Exercise and Lifestyle Changes36:03 Diet and Nutrition Misconceptions37:54 Balancing Career and Health40:27 The Recurrence and New Insights47:03 The 10% Toxic Philosophy50:06 Practical Tips for a Healthier Life01:02:48 Final Thoughts and Conclusion

Send us a textUnderstanding the Sacroiliac Joint: Causes, Diagnosis, and TreatmentIn this episode of PTs Snacks podcast, we cover the often misunderstood sacroiliac (SI) joint, explaining its anatomy and function. Listeners will learn about the causes of SI joint pain and the risk factors associated with it. We also discuss methods for diagnosing SI joint pain and effective treatments.00:00 Introduction to PTs Snacks Podcast00:58 Overview of the Sacroiliac (SI) Joint01:28 Anatomy and Function of the SI Joint02:59 Causes and Risk Factors of SI Joint Pain04:13 Symptoms and Differential Diagnosis06:48 Provocative Tests for SI Joint Pain09:31 Imaging and Injections for Diagnosis10:43 Treatment Options for SI Joint Pain11:32 Conclusion and Additional ResourcesResources:Nejati P, et al. Effectiveness of exercise therapy and manipulation on sacroiliac joint dysfunction: a randomized controlled trial. Pain Physician. 2019;22(1):53-61.Trager R, et al. Efficacy of manual therapy for sacroiliac joint pain syndrome: a systematic review and meta-analysis of randomized controlled trials. Musculoskelet Sci Pract. 2024;67:102815.Doğan N, et al. Effects of mobilization treatment on sacroiliac joint dysfunction syndrome. Pain Res Manag. 2021;2021:6613629.Javadov A, et al. The efficiency of manual therapy and sacroiliac and lumbar exercises in patients with sacroiliac joint dysfunction syndrome. Turk J Phys Med Rehabil. 2021;67(2):129-36.Cerasoli T, et al. Injective therapies for managing sacroiliac joint pain in spondyloarthropathy: a systematic review and meta-analysis. 2025.Gartenberg A, et al. Sacroiliac joint dysfunction: pathophysiology, diagnosis, and treatment. Curr Rev Musculoskelet Med. 2021;14(6):414-21.Liu Y, et al. Comparative efficacy of clinical interventions for sacroiliac joint pain: systematic review and network meta-analysis with preliminary design of treatment algorithm. Pain Physician. 2023;26(2):123-34.Polly D, et al. Two-year outcomes from a randomized controlled trial of minimallGo to PT Final Exam using this link to access great studying options to conquer the NPTE!Support the showStay Connected! Make sure to hit follow now so you don't miss an episode! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. You can also join the email list HERE Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less! Prepping for the NPTE? Get all the study tools you need to master it at PT Final Exam. Use code PTSnacks at checkout to get a discount! Want to Support the Show?Help me keep creating free content by: Sharing the podcast with someone who'd benefit. Contributing directly via the link...

Send us a textADHD is one of the most common concerns parents bring up—but it's also one of the most misunderstood. What does ADHD really mean? How is it diagnosed? And what actually helps kids who struggle with focus, organization, or impulsivity?In this episode of Your Child Is Normal, Dr. Jessica Hochman sits down with ADHD specialist Shirley Hershko, who brings both professional expertise and personal experience as a parent of children with ADHD. Together, they explore:What ADHD looks like in the brain (and why dopamine plays such a big role)Why girls are often missed or misdiagnosedHow to think about diagnosis when symptoms feel “subjective”Medication vs. non-medication options—what parents should knowPractical behavioral tools and environmental supports for kidsHow to reframe ADHD as not just a challenge, but also a source of creativity, empathy, and resilienceResources & Apps Mentioned in This Episode:Google Calendar – for scheduling and time managementTrello – for visual task management and organizationMyHomework – homework planning app to keep assignments on trackBook & Website:ADHD Is Our Superpower: The Amazing Talents and Skills Behind the Symptoms by Dr. Shirley Hershko Learn more at drshirleyhershko.comWhether you're just starting to wonder if your child may have ADHD or you're already navigating daily life with it, this conversation is full of insight and reassurance.Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditi...

In this powerful episode of Keeping Abreast, Dr. Jenn Simmons welcomes advocate Donna Pinto to uncover the truth about DCIS (ductal carcinoma in situ), mammography, and the epidemic of overdiagnosis.Donna shares her personal journey from shock diagnosis to advocacy, exposing how fear, language, and profit drive women into unnecessary treatments. Together, she and Dr. Jenn highlight the emotional toll of mislabeling DCIS as cancer, the shortcomings of mammograms, and the need for safer, smarter approaches.

Statistics show about 60% of inmates have a substance abuse disorder, yet drugs are commonly smuggled inside U.S. jail facilities, contributing to overdose deaths in custody. And when jails have treatment options like methadone and Suboxone, there often aren't enough to go around. Here & Now's Peter O'Dowd reports from a jail in Albuquerque, New Mexico.And, Richard Graham died of an overdose in a Louisville, Kentucky, jail. As his family mourns the loss, they're looking for answers. And so is the city; In 2022, Louisville Metro Council launched an investigation after a spike in overdose and suicide deaths. O'Dowd talks with Richard Graham's family and Louisville jail officials about why overdoses are so common and what can be done to curb them.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Each week in the U.S., about 200 people are diagnosed with multiple sclerosis (MS), and women are four times more likely than men to develop it. What are the warning signs? What challenges do patients face? And how can they advocate for themselves? We spoke with Mitzi Joi Williams, MD, a board-certified neurologist, to discuss health disparities that delay diagnosis in underserved communities, stigmas that prevent women from seeking care, and why early detection is crucial for long-term health. We also hear from Angelina Cubero, diagnosed in 2020, who shares her story and how self-advocacy shaped her journey. Tune in to learn how preparing for medical visits, recognizing symptoms, and finding peer support can empower those living with MS.See omnystudio.com/listener for privacy information.

In today's episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.   In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

Benign prostatic hyperplasia (BPH) impacts many men at some point as they age. Ramsay Kuo, MD, discusses why treatment is so important, and the growing number of options men have to improve quality of life and prevent irreversible bladder damage.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

For more info and support, visit us at https://thecirsgroup.com In this episode of The CIRS Group podcast, hosts Jacie and Barbara dive into the autoimmune condition known as Alopecia Areata. You may be familiar with it because of Jada Pinkett Smith (and the slap heard round the world) or more recently because of Dallas Cowboys Cheerleader Armani Latimer's brave story on the second season of the Netflix docuseries, America's Sweethearts. Today, we'll cover those stories and Barbara will share her journey with the condition as well. They'll also explore what Alopecia Areata is, as well as its triggers, symptoms, and the connection to Chronic Inflammatory Response Syndrome (CIRS). They also touch on treatment options, genetic predispositions, and related autoimmune conditions. Tune in to learn more about managing this rare condition and how it may relate to other health issues. For more info and support, visit us at https://thecirsgroup.com TIMESTAMPS 00:00 Welcome to The CIRS Group Podcast 00:24 Introduction and medical disclaimer 00:48 Barbara's Personal Experience with Alopecia 02:11 Alopecia in the Media 05:24 What is Alopecia Areata? 07:15 Barbara's alopecia areata timeline 08:56 Causes and Triggers of Alopecia 10:50 What Alopecia Areata is NOT 12:06 Prevalence and levels of severity of Alopecia 14:40 Risk factors for Alopecia 16:48 Treatment Options for Alopecia 19:48 Connecting autoimmune illnesses and CIRS 22:29 Conclusion and Final Thoughts Order Jacie's book! The 30 Day Carnivore Bootcamp: https://a.co/d/7MgHrRs The CIRS Group: Support Community: https://thecirsgroup.com Instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Jacie's book on the Carnivore diet!  https://a.co/d/8ZKCqz0 Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, writer, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

Emotional lability, anxiety, crying jags. Welcome to perimenopause. 70% of women experience depressive symptoms and alterations in mood when estrogen levels plunge or start to fluctuate.  While many factors increase the risk, there is no denying that changes in hormone levels have something to do with anxiety, mood, and depression, even in people who never had issues before perimenopause.     Dr. Pauline Maki is a world-renowned expert in menopause, mood, cognition, and the impact of menopause on the brain. She has authored hundreds of scientific articles and leads a National Institutes of Health (NIH) funded research program on women, cognition, mood, and dementia.  In this episode, we take a deep dive into the science of why women have mood alterations and depression when estrogen levels start to fluctuate.   In this episode:  ·      What it was like to participate in Dr. Jill Biden's  White House Initiative on Women's Health Research ·      The difference between depressive symptoms, mood alteration and depression ·      The risk of recurrence if there is a history of depression during perimenopause ·      The risk of developing depression if there is no history of depression ·      The risk of developing mood alterations if there is no history of depression ·      Windows of vulnerability (pregnancy, post-partum, perimenopause)  ·      What is occurring hormonally in the brain at the level of progesterone and estrogen receptors  ·      The Science Behind Risk Factors for developing depressive symptoms or depression during perimenopause o   Early menopause o   BRCA mutations o   History of major depressive disorder o   Hormone sensitivity in the brain o   Severe menopause symptoms  o   Childhood experiences o   Current life stressors ·      Treatment Options for Perimenopausal Depressive Symptoms o   No treatment- when will it go away? o   Cognitive Behavioral Therapy o   SSRIs o   Hormone Therapy o   NK3 Agonists  o   Progesterone?

Ready to take charge of your health and feel your best? Today, Dr. Robert Whitfield speaks with filmmaker Brian Sanders to discuss how nutrition and smart food choices play a significant role in our overall health. Dr. Whitfield talks about what he's learned from helping patients recover from breast implant illness, while Brian shares his own story of turning his health around by changing his diet. They both emphasize the perks of eating whole foods, getting enough protein, and cutting back on processed stuff. You'll also hear some down-to-earth tips for eating healthy on a budget and why making lifestyle changes really matters. If you're ready to turn your health around, tune in! Bio: Brian Sanders Brian Sanders is the filmmaker behind the Food Lies documentary, host of the top 5 nutrition podcast Peak Human, and an international speaker. He graduated from UCLA with a degree in Mechanical Engineering, and he's the founder of Sapien Center, a popular health club in Austin. He also owns the grass-fed meat & beef tallow body care company, Nose to Tail. https://www.indiegogo.com/projects/food-lies-post#/https://www.indiegogo.com/projects/food-lies-post#/ https://www.peak-human.com/https://www.peak-human.com/ http://sapiencenter.com/ (http://sapiencenter.com/) https://nosetotail.org/ (https://nosetotail.org/) Show Highlights: Challenges in Changing Habits (00:04:00) The difficulty of changing unhealthy habits, especially for families and children Enjoyable & Sustainable Healthy Eating (00:08:21) *How healthy eating can be enjoyable and sustainable *Sugar Addiction & Satiety (00:13:36) Sugar addiction and satiety Processed vs. Ultra-Processed Foods (00:17:33) Ultra-processed foods and their negative health impacts Food Processing Categories (00:19:48) Three food categories: whole foods, traditionally processed, and industrially processed foods Movement & Walking as Essential (00:24:29) *Daily movement and walking for metabolic health *Protein Focus & Adaptability When Traveling (00:30:09) *Tips for maintaining a protein-focused diet while traveling *Stepping Down from Unhealthy Snacks (00:32:04) Strategies for transitioning from unhealthy snacks, like chips, to better alternatives Protein for Healing & Patient Care (00:38:28) Dr. Whitfield discusses the necessity of protein for healing, especially in surgical patients Affordable Healthy Eating & Cooking Tips (00:40:28) Advice on sourcing affordable protein, simple cooking methods, and prioritizing unprocessed foods Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield

In this powerful follow-up episode, Jamie and Teresa dive deep into Hashimoto's Thyroiditis and Hypothyroidism, taking the conversation to the next level with a focused discussion on treatment options. If you've been diagnosed with thyroid dysfunction or suspect something's off with your thyroid health, this is the episode for you. Teresa and Jamie break down every type of thyroid hormone replacement therapy, helping you navigate the often confusing world of thyroid care:

Summary In this episode, Ali Damron discusses the complexities of perimenopausal symptoms, emphasizing the significant role of the nervous system in amplifying these symptoms. She explores the differences in how women experience hormonal fluctuations and the importance of addressing both hormonal and nervous system health for effective treatment. The conversation also covers various treatment options, including HRT and antidepressants, and highlights the necessity of managing stress and integrating neuroplasticity strategies for lasting relief. Takeaways Perimenopausal symptoms vary greatly among women. The nervous system significantly influences symptom severity. Hormonal fluctuations are not the sole cause of symptoms. HRT can be beneficial for many women. Stress management is crucial for symptom relief. Integrating neuroplasticity can enhance treatment outcomes. Women often feel broken due to ineffective treatments. Teaching the brain to feel safe is essential. Both hormonal and nervous system support are necessary. A holistic approach is key to managing perimenopausal symptoms. Titles Navigating Perimenopause: Understanding Symptoms The Nervous System's Role in Women's Health Chapters 00:00 Understanding Perimenopausal Symptoms 02:48 The Role of the Nervous System 06:02 Hormonal Fluctuations and Their Impact 08:55 Conventional vs. Alternative Treatments 12:02 The Importance of Stress Management 15:07 Integrating Neuroplasticity in Treatment 17:58 Breaking the Symptom Cycle 21:09 Strategies for Nervous System Regulation 23:51 Final Thoughts on Healing and Support   Ali's Resources:  Calm the Chaos: Practical Tips and Tools for Stopping Anxiety in It's Tracks Course! Consults with Ali  BIOptimizers Magnesium Breakthrough 10% off using code ALIDAMRON10 www.alidamron.com/magnesium Master Your Perimenopause Course + Toolkit "Am I in Perimenopause?" Checklist.  What Hormone is Imbalanced? Quiz! Fullscript (Get 10% off all supplements) "How To Balance Your Hormones For Better Sleep, Mood, Periods and Energy" Free, On Demand Training Website  Ali's Instagram Ali's Facebook Group: Holistic Health with Ali Damron   

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a conversation about soft tissue sarcoma management. Drs Armstrong and Tawagi discussed that soft tissue sarcomas represent a rare and heterogeneous group of malignancies that arise from mesenchymal cells rather than epithelial cells and encompass several distinct histologic subtypes. They explained that although uncommon, these sarcomas are frequently emphasized in board examinations, partly because their management has historically been stable, though recent FDA approvals and ongoing research have expanded therapeutic options. They noted that risk factors may include prior radiation exposure, environmental agents, and viral infections. Additionally, they shared that chronic lymphedema is associated with angiosarcoma, whereas rare hereditary syndromes may predispose individuals to specific sarcoma subtypes.  Clinically, they explained that sarcomas may arise anywhere in the body, though many occur in the thigh, buttocks, or groin, typically presenting as painless, enlarging masses often mistaken for benign lesions. They emphasized that diagnosis requires core needle biopsy to preserve tissue architecture and that staging relies on MRI of the primary site and CT of the chest, given the strong predilection for pulmonary metastases. They also summarized the five subtypes of soft tissue sarcoma—synovial, clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid. They reported that the cornerstone of localized disease management is surgical resection, preferably limb-sparing when feasible, combined with radiation for larger or high-risk tumors. They also highlighted novel strategies like immunotherapy. For metastatic disease, they stated that surgical resection of pulmonary metastases can achieve durable remissions in select patients. 

Mark A. Stein, Ph.D., will provide an overview of pediatric ADHD treatment options, explain why it's crucial to personalize treatment, and how to combine and sequence medication and other treatments for optimal care. ADHD Treatments for Children: Additional Resources Free Download: Take Charge of Your Child's Medication Read: ADHD Treatment Options for Children Read: What Is Complex ADHD? Symptoms, Diagnosis & Treatment Read: How a Physician Treats ADHD with Combination Therapy Access the video and slides for podcast episode #571 here: https://www.additudemag.com/webinar/adhd-treatment-options-combination-therapy/ This episode is sponsored by the podcast Hyperfocus with Rae Jacobson. Search for “Hyperfocus with Rae Jacobson” in your podcast app or find links to listen at https://lnk.to/hyperfocusPS!adhdexperts. This episode is also brought to you by Brain.fm. Unlock your brain's full potential FREE for 30 days by going to brain.fm/ADDITUDE. Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

Treatment strategies for different varieties of SIBO. A continuation of our burning SIBO questions. Topics for part two: Most effective treatment strategies for methane and hydrogen SIBOMaking sense of hydrogen sulfide SIBO,Dr. Gurevich's favorite herbal treatment optionsHow and why to support patients through the dreaded elemental diet. 

In this Varroa Treatments short, Jeff Ott and co-host Dr. Becky Masterman welcome Dr. David Peck from Betterbee to discuss formic acid—a powerful tool in the fight against varroa mites. David explains how Formic Pro, the most common formic acid product now available in the U.S., is formulated to safely release vapors that penetrate capped brood cells, killing mites both on adult bees and developing brood. David and Becky highlight both the strengths and cautions: formic acid's ability to deliver a fast, thorough mite knockdown, its temperature sensitivity, and its potential to cause temporary brood loss or even queen replacement in stressed colonies. They emphasize protective gear, ventilation requirements, and why strong colonies benefit most from treatment. From freezer tricks to reduce fumes, to understanding normal bee behaviors like bearding after application, this episode gives beekeepers the knowledge to use formic acid effectively and safely—making it a valuable addition to a year-round mite management plan. Links & Resources: Honey Bee Health Coalition: https://honeybeehealthcoalition.org/resources/varroa-management/  Betterbee Pest Management Resource Page: https://www.betterbee.com/instructions-and-resources/pest-management.asp   Brought to you by Betterbee – your partners in better beekeeping. ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com Copyright © 2025 by Growing Planet Media, LLC